LONDON, April 24, 2026, 20:06 BST
Convatec Group Plc dropped in London trading on Friday, putting the FTSE 100 medical-products company back in the spotlight. Investors are now sizing up its 2026 growth ambitions, with new signals of weakness emerging in certain segments of the wound-care market.
Convatec shares finished the day at £2.21, down 1.69%—a steeper drop than the broader market. The closing price, according to MarketWatch, leaves the stock trading 29.05% beneath its 52-week high of £3.11.
That’s suddenly in focus after Coloplast, the Danish medical products group, slashed its 2025/26 outlook late Thursday. Blaming a sluggish U.S. recovery in skin-substitute outpatient sales for its Kerecis wound-care arm, the company trimmed its group organic growth target to 5%–6% from about 7%. Coloplast also recorded a DKK 3.0 billion goodwill impairment tied to Kerecis.
Convatec faces some of that risk itself via InnovaMatrix, its skin-graft line impacted by changes in U.S. Medicare reimbursement. Medicare reimbursement refers to what the U.S. government insurance program pays for care for older and disabled patients.
Back in February, the company flagged that InnovaMatrix revenue would likely drop to around $20 million by 2026, dragging overall group revenue down by about 2% for that year, and causing a roughly 3% hit in the first half. Despite this, management stuck to its outlook: organic revenue growth between 5% and 7%, not counting InnovaMatrix, with adjusted operating margin seen at no less than 23%, and adjusted earnings per share still on track for double-digit gains. Organic revenue, as defined by the company, excludes swings in currency and any impact from acquisitions or disposals.
Back in February, Reuters said Convatec bumped its medium-term organic revenue growth target to 6%-8%, up from the previous 5%-7% range, following a more than 12% jump in adjusted operating profit to $544 million. The company’s argument? Chronic care needs, a fresh product lineup, and tighter execution are supposed to counterbalance sluggishness in the wound-care unit.
At an April 9 capital markets day, Chief Executive Jonny Mason pressed the point, rolling out Convatec’s “Accelerate” strategy. Mason described a “substantial” opportunity for future growth, citing aging demographics, a rise in chronic disease, and what the company described as its strongest innovation pipeline to date. Convatecgroup
This week, the group named Peter Jarvis as chief operations officer, effective June 1. Jarvis, who previously held a senior supply-chain role at Vantive—Baxter’s former kidney-care arm—steps in to oversee Convatec’s global operations and manufacturing. Mason pointed to Jarvis’s “exceptional track record” in operations, quality, and transformation. Convatecgroup
Rivals aren’t idle. Smith+Nephew, the UK-listed medical device maker, rolled out its ALLEVYN COMPLETE CARE foam dressing back in March, targeting both wound management and the prevention of pressure injuries. Coloplast is still right up there as a peer in ostomy, continence, and wound care.
There’s a risk U.S. reimbursement pressure could linger, or even extend deeper into Convatec’s wound-care lineup. Tariff expenses and stepped-up investment are already squeezing margins. Convatec has also flagged a U.S. FDA warning letter at its infusion-care arm, Unomedical, but said the letter didn’t touch on product safety or halt production, marketing, manufacturing, or distribution.
The next look at Convatec comes on May 21, with its AGM and a trading update covering the four months to April 30. For now, Friday’s share price shift puts the focus squarely on whether the company’s fresh strategy can weather a tougher U.S. wound-care landscape.
